![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
/βDepartment of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (T.S., R.K., H.K., Y.S.); and Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (I.K., F.J.G.)
Received July 6, 2007; accepted November 19, 2007.
| Abstract |
|---|
|
|
|---|
(Hnf1
)-null mice. However, in vitro evidence for the involvement of HNF1
and further analyses are required to illustrate the transcriptional regulation of OAT1 genes in more detail. Computational analysis of the potential transcription factor binding sites revealed that the HNF1-motif was conserved in the proximal-promoter region of human and mouse OAT1 genes. The mRNA expression of mouse organic anion transporter 1 was drastically reduced in Hnf1
-null mice compared with that in wild-type mice, which was consistent with a previous report (Maher et al., 2006
alone or both HNF1
and HNF1β enhanced the activity of human and mouse OAT1 promoters in the transactivation assays, whereas HNF1β alone was not active. Mutations in the HNF1-motif significantly reduced this transactivation. Direct binding of HNF1
/HNF1
homodimer and HNF1
/HNF1β heterodimer to the HNF1-motif found in the human OAT1 promoter was demonstrated by electrophoretic mobility shift assays. These results provide convincing evidence for the involvement of HNF1
/β in the constitutive expression of human and mouse OAT1 in the kidney.
We have recently characterized the transcriptional regulation of OAT3 and urate transporter 1 (URAT1/SLC22A12) and shown that the coordinated action of hepatocyte nuclear factor 1
/β (HNF1
/β) and DNA methylation determines the kidney-specific expression of these transporters (Kikuchi et al., 2006
, 2007
). HNF1 consists of two isoforms, HNF1
and HNF1β, and activates the transcription of target genes via direct binding to their promoters after forming homodimers or heterodimers between the two isoforms (Mendel and Crabtree, 1991
; Tronche and Yaniv, 1992
). These transcription factors were originally identified to be involved in the maintenance of hepatic gene expression, such as albumin,
1-antitrypsin, and
- and β-fibrinogen, as well as some of the organic anion transporters in the liver (Shih et al., 2001
). As a result, cumulative reports including the analyses of gene-disrupted animals suggest the importance of HNF1
/β in extrahepatic organs, such as the pancreas and kidney (Pontoglio et al., 1996
; Lee et al., 1998
; Gresh et al., 2004
).
In the kidney, HNF1
exhibits restricted distribution within the proximal tubules, whereas HNF1β is expressed along the entire nephrons (Lazzaro et al., 1992
; Pontoglio et al., 1996
). HNF1 normally exists as the HNF1
/HNF1β heterodimer or HNF1β/HNF1β homodimer in the proximal tubules, whereas HNF1β/HNF1β homodimer is predominantly expressed in the other segments. As for renal organic anion transporters, mRNA expression of Oat1, as well as Oat2 and Oat3 in the kidney, is reduced in Hnf1
-null mice, suggesting the role of HNF1
in the transcription of organic anion transporters not only in the liver but also in the kidney (Maher et al., 2006
). Computational analysis of the human and mouse OAT1 5'-flanking sequences revealed that the HNF1-motif is conserved in the proximal-promoter region of OAT1 genes (Fig. 1). On the other hand, Ogasawara et al. (2007
) recently reported that HNF4
, an orphan member of the nuclear receptor superfamily, enhances the promoter activity of human OAT1, whereas the effect of HNF1
or HNF1β was minimal. HNF4
forms homodimers to bind to a DNA sequence corresponding to a direct repeat of AGGTCA-like hexamers separated by one or two nucleotides (DR1 or DR2, respectively) or an inverted repeat of the hexamers separated by eight nucleotides (IR-8) (Sladek et al., 1990
; Fraser et al., 1998
; Prieur et al., 2005
) and regulates the hepatic expression of human organic anion transporter 2 (SLC22A7) and organic cation transporter 1 (SLC22A1) under both physiological and pathological conditions (Popowski et al., 2005
; Saborowski et al., 2006
). Although HNF4
is found in the proximal tubules in the kidney (Jiang et al., 2003
), the physiological significance of HNF4
in the kidney is poorly recognized due to the embryonic death of Hnf4
-null mice (Chen et al., 1994
). Furthermore, it has yet to be investigated whether HNF1
/β is actually involved in the transcription of the human OAT1 gene, as is the case with OAT3 and URAT1.
|
and/or HNF1β is involved in the transcriptional regulation of human and mouse OAT1 genes and to further confirm the importance of HNF1 in the regulation of organic anion transporters in the kidney. | Materials and Methods |
|---|
|
|
|---|
Preparation of Total RNA and Quantitative Polymerase Chain Reaction. Total RNA was isolated from the kidney of 7 to 14-week-old male (n = 3) and female (n = 4) wild-type or Hnf1
-null mice (Lee et al., 1998
), and it was treated with DNase I to eliminate the contaminated genomic DNA. The total RNA was reverse-transcribed using a random-nonamer primer (Takara, Shiga, Japan), and real-time quantitative polymerase chain reaction (PCR) was performed as previously described (Kikuchi et al., 2006
) using the primers shown in Table 1 to quantify the mRNA expression of mouse organic anion transporter 1 (mOat1). The mRNA expression of mOat1 was normalized by the mRNA expression of GAPDH and statistically analyzed by the Student's t test.
|
Isolation of the 5'-Flanking Region of the hOAT1 and mOat1 Genes. The transcriptional start site of the hOAT1 and mOat1 gene was identified based on the information in the public database, Database of Transcriptional Start Sites (http://dbtss.hgc.jp/), with the reference sequence identification for hOAT1 and mOat1 (NM_004790 and NM_008766, respectively). The position of the potential transcription factor binding sites in human and mouse OAT1 promoter regions was determined using MatInspector (http://www.genomatix.de/) or NUBIScan (http://pages.unibas.ch/wtt/Products/Nubiscan/nubiscan.html) (Podvinec et al., 2002
). The 919- and 110-base pair (bp) 5'-flanking regions of the human and mouse OAT1 gene were amplified by PCR using human and mouse genomic DNA as a template, respectively. An artificial KpnI or HindIII restriction site was added to the primer sequences, which are shown in Table 1. The PCR products were digested with KpnI and HindIII after subcloning into pGEM-T Easy vector (Promega, Madison, WI) and ligated into pGL3-Basic vector (Promega) predigested with KpnI and HindIII, yielding the hOAT1_-919/+11_HNF1wt and mOat1_-110/+10_HNF1wt promoter-reporter construct. A series of hOAT1 5'-truncated promoter fragments (-623/+11, -318/+11, and -111/+11) were PCR-amplified using hOAT1_-919/+11_HNF1wt plasmid as a template (the primers are shown in Table 1) and then inserted into the pGL3-Basic vector as described above, yielding the following promoter constructs: hOAT1_-623/+11_HNF1wt, -318/+11_HNF1wt, and -111/+11_HNF1wt. The sequence identity of all the constructs with the respective genomic sequences was verified by DNA sequencing. Plasmid DNA was prepared using the GenElute Plasmid Midiprep kit (Sigma-Aldrich, St. Louis, MO).
Site-Directed Mutagenesis. All of the mutated promoter fragments (HNF1mut) having a 4-bp-disrupted HNF1-motif were generated with a QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) using internally mutated oligonucleotides with sense sequence (as shown in Table 1) according to the manufacturer's instructions. The introduction of mutations was verified by DNA sequencing. The positions and bases that will replace the original sequences were decided based on the information in the database of transcription factors TRANSFAC (http://www.gene-regulation.com/); highly conserved bases in the consensus HNF1-motif were mutated into bases with the lowest frequency at the corresponding position.
Cell Culture, Transfections, and Luciferase Assays. Cell culture and transfections were performed as described previously. In transactivation assays, 0.5 µg of empty pcDNA3.1+ control vector, 0.5 µg of HNF1
expression vector, 0.25 µg of HNF1
and HNF1β expression vectors, or 0.5 µg of HNF1β expression vector was cotransfected with 0.5 µg of the corresponding promoter construct and 0.05 µg of internal standard pRL-SV40 into HEK293 cells. The promoter activity was measured as relative light units of firefly luciferase per unit of Renilla luciferase. The difference in the promoter activity between wild-type and HNF1-mutated reporter constructs was statistically analyzed by the Student's t test.
In Vitro Translation. In vitro translation was performed using TNT Quick Coupled Transcription/Translation kits (Promega) according to the manufacturer's instructions. One microgram of empty pcDNA3.1+ control vector, 1 µg of HNF1
expression vector, 0.5 µgof HNF1
and HNF1β expression vectors, or 1 µg of HNF1β expression vector was added to the TNT Quick master mix. The mixture was then incubated at 30°C for 75 min and used for additional analyses. The HNF1
and HNF1β proteins were prepared at least twice, and the reproducible binding to the labeled OAT1 probe was confirmed.
Electrophoretic Mobility Shift Assay. Double-stranded oligonucleotide probes were generated by hybridizing single-stranded complementary oligonucleotides with sense sequences (shown in Table 1). The sequence "wt" corresponds to the wild-type HNF1-motif found in the hOAT1 promoter, and "per" corresponds to the perfect consensus sequence for the HNF1-motif, whereas "mut" denotes the wild-type sequence mutated in the motif. Electrophoretic mobility shift assay (EMSA) was performed as previously described with Dig Gel Shift Kit, 2nd Generation (Roche Diagnostics, Indianapolis, IN) (Kikuchi et al., 2006
). In brief, 2.5 µl of in vitro-translated HNF1
and/or HNF1β was incubated on ice for 30 min in the binding solution containing 0.92 pmol of digoxigenin-labeled probe. A 100-fold excess of unlabeled oligonucleotides and 1 µg of antibody against HNF1
or HNF1β (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were added to the reaction for competition and supershift assays, respectively. The experiments were independently performed three times, and the representative images are shown.
| Results |
|---|
|
|
|---|
Impaired Expression of mOat1 in the Kidney of Hnf1
-Null Mice. The mRNA expression of mOat1 in male and female Hnf1
-null mice was measured by real-time quantitative PCR (Fig. 2). The expression of mOat1 mRNA was approximately 3-fold higher in male kidney than in female in wild-type controls, which is consistent with the previous findings (Buist and Klaassen, 2004
). Inactivation of HNF1
led to a significant reduction in the expression of mOat1 in male mice. In females, the expression of mOat1 mRNA was reduced by two-thirds in Hnf1
-null mice compared with wild-type mice. These results clearly document the importance of HNF1
in the transcriptional regulation of the mOat1 gene in the kidney.
|
/β. We have previously demonstrated that endogenous expression of HNF1
and HNF1β is negligible in HEK293 cells (Kikuchi et al., 2006
and/or HNF1β on OAT1 gene promoter activity. The protein expression of exogenously transfected HNF1
or HNF1β in HEK293 cells was confirmed by Western blot analysis after preparation of nuclear extracts from those cells (data not shown). The promoter activity of mOat1 was stimulated by cotransfection of HNF1
alone or both HNF1
and HNF1β, whereas HNF1β alone did not show any enhancement (Fig. 3A). These results provide mechanistic evidence for the involvement of HNF1
in the transcription of mOat1 in the kidney.
|
and/or HNF1β regulate hOAT1-promoter activity, a series of 5'-truncated-promoter constructs of hOAT1, with or without the mutation in the HNF1-motif, was cotransfected with HNF1
and/or HNF1β into HEK293 cells, and the luciferase activity was measured (Fig. 3B). All of the wild-type promoter constructs showed a marked increase in luciferase activity by forced-expression of HNF1
alone or both HNF1
and HNF1β compared with the pcDNA3.1+-transfected control. The effect of HNF1β on the promoter activity of hOAT1 was not marked, regardless of the length of the promoter construct. No additional enhancement was observed by extending the hOAT1 promoter from -111 to -919, suggesting that HNF1
/β binds to the hOAT1-promoter region within 111 bp upstream of the transcriptional start site, where the HNF1-motif was found. The functional relevance of this HNF1-motif was investigated by introducing mutations into the motif. The increase in the luciferase activity caused by the forced expression of HNF1
alone or both HNF1
and HNF1β was attenuated by approximately 50 to 70% in the HNF1-motif-mutated reporter compared with the wild-type reporter. These results strongly suggest that the HNF1-motif found in the hOAT1-proximal promoter is essential for transactivation of the promoter activity by HNF1
alone or both HNF1
and HNF1β.
Direct Binding of HNF1
/β to the hOAT1 Promoter. To confirm the direct binding of HNF1
/β to the hOAT1 promoter, EMSA was performed with the oligonucleotide probe corresponding to the HNF1-motif found in the hOAT1 promoter and in vitro-translated HNF1
and/or HNF1β (Fig. 4A). The expression of in vitro-translated HNF1
or HNF1β was confirmed by Western blot analysis with specific antibodies against HNF1
or HNF1β, respectively (data not shown). When the probe was incubated with HNF1
alone or both HNF1
and HNF1β, one- (Fig. 4A, band a, lane 3) or two-shifted bands (Fig. 4A, bands a and b, lane 7) were observed, respectively, whereas there was no shifted band when the probe was incubated with HNF1β alone (lane 11). In all samples using the in vitro-translated products, a broad signal was detected below the bands (Fig. 4A, bands a and b). It is likely that this signal represents nonspecific binding to the labeled probe because the signal was also detected when in vitro-translated empty pcDNA3.1+ was incubated with the probe (Fig. 4A, lane 2). Formation of both bands a and b (Fig. 4A) was completely abolished by adding a 100-fold excess of the unlabeled competitor corresponding to the consensus sequence for the HNF1-motif (Fig. 4A, lanes 4 and 8) and partly inhibited by the competitor corresponding to the hOAT1 wild-type promoter sequence (Fig. 4A, lanes 5 and 9). On the other hand, these bands were not affected by the addition of the mutated competitor (Fig. 4A, lanes 6 and 10). These results suggest that bands a and b (Fig. 4A) can be ascribed to the binding of HNF1
or HNF1β to the HNF1-motif in the hOAT1 promoter.
|
or HNF1β (Fig. 4B). The addition of an anti-HNF1
antibody resulted in the supershift of both bands a and b (Fig. 4B, lanes 2 and 5), whereas the addition of anti-HNF1β antibody abolished band b but not band a (Fig. 4B, lanes 3 and 6). The supershifted bands were barely detectable when both HNF1
and HNF1β were incubated with the labeled probe (Fig. 4B, lanes 5 and 6), probably due to the low intensity of the shifted bands. The mobility of bands a and b (Fig. 4B) in the present study nearly coincides with that of the shifted bands that reflect the interaction of HNF1
/HNF1
homodimer and HNF1
/HNF1β heterodimer with the HNF1-motif in hOAT3 and human URAT1 promoters, respectively (Kikuchi et al., 2006
/HNF1
homodimer and HNF1
/HNF1β heterodimer, respectively.
| Discussion |
|---|
|
|
|---|
and/or HNF1β play a critical role in the expression of drug transporters in the liver and kidney. Several groups, including us, have shown that the HNF1-motif located within approximately 100 bp of the 5'-flanking region is involved in the transcriptional regulation of these transporters, i.e., -65 to -53 in the OAT3 promoters, -70 to -58 in the URAT1 promoters, -51 to -39 in the organic anion-transporting polypeptide 1B1 promoter, and -60 to -48 in the organic anion-transporting polypeptide 1B3 promoter (Jung et al., 2001
-null male mice (Maher et al., 2006
/β in the transcriptional regulation of human and mouse OAT1 genes.
The involvement of HNF1
and/or HNF1β in the transcriptional regulation of human and mouse OAT1 genes was revealed by in vivo (Fig. 2) and in vitro experiments (Figs. 3 and 4). It is generally accepted that the transactivation potency of HNF1β is lower than that of HNF1
(Rey-Campos et al., 1991
). Indeed, exogenous expression of HNF1β alone enhanced the promoter activity of OAT3 and URAT1 by at most 50% compared with that of HNF1
alone (Kikuchi et al., 2006
, 2007
). In the present study, HNF1β alone hardly stimulated the promoter activity of the human and mouse OAT1 genes, and no direct binding of HNF1β/HNF1β homodimer to the hOAT1 promoter could be detected. HNF1β exhibited less activity against the OAT1 promoters than OAT3 and URAT1 promoters. Therefore, it is likely that the contribution of HNF1β/HNF1β homodimer to the expression of OAT1 is much smaller than that of OAT3 and URAT1.
Ogasawara et al. (2007
) demonstrated that HNF4
markedly transactivated the hOAT1 promoter through direct binding to the IR-8 element, whereas neither HNF1
nor HNF1β affected the promoter activity. On the other hand, we have provided clear evidence for an essential role of HNF1
in human and mouse OAT1 expression. We also confirmed that HNF4
transactivates the hOAT1 promoter. Cotransfection of HNF4
into HEK293 cells enhanced the promoter activity of the hOAT1_-919/+11_HNF1wt construct 3-fold compared with the pcDNA3.1+-transfected control (data not shown). Therefore, the experimental conditions may not be appropriate for examining the effect of HNF1
/β in the previous report. The two studies used different cell lines as host. We used HEK293 cells that lack the endogenous expression of HNF1
/β, whereas Ogasawara et al. (2007
) used OK cells in which the endogenous expression of HNF1
/β has not been investigated. The following difference in the reporter construct used could be another reason: hOAT1_-2747/+88 (Ogasawara et al., 2007
) versus hOAT1_-919, -623, -318, or -111/+11_HNF1wt (present study).
In the kidney, the expression of both HNF1
and HNF4
is restricted to the proximal tubules (Lazzaro et al., 1992
; Pontoglio et al., 1996
; Jiang et al., 2003
), consistent with the regional distribution of hOAT1 (Hosoyamada et al., 1999
). Thus, the proximal tubule-specific expression of hOAT1 in the kidney is, at least partly, explained by the concerted effect of HNF1
/HNF1β heterodimer and HNF4
/HNF4
homodimer. However, the tissue distribution of HNF1
β and HNF4
is much wider than that of OAT1 (Sladek et al., 1990
; Blumenfeld et al., 1991
; Rey-Campos et al., 1991
; Miquerol et al., 1994
; Drewes et al., 1996
). Although OAT1 is exclusively expressed in the kidney, HNF1
, HNF1β, and HNF4
are expressed in extrarenal tissues, such as the liver, intestine, and pancreas. We have recently shown that the kidney-specific expression of OAT3 and URAT1 genes is regulated by the synergistic effect of transcriptional activation by HNF1
/β and repression by DNA methylation in the promoter region. However, unlike the minimal promoter regions of hOAT3 and human/mouse URAT1, there are few CpG dinucleotides in the human and mouse OAT1 promoter regions up to -400 bp (Fig. 1). It is noteworthy that OAT1 and OAT3 genes occur as a tightly linked pair on the same chromosome in the human and mouse genome with intergenic distances of 8.3 kilobase pairs in humans and 7.5 kilobase pairs in mice (Eraly et al., 2003
). Both genes are transcribed to the same direction with OAT3 upstream of OAT1. The clustering of OAT1 and OAT3 in the genome raises the possibility that the methylation status of the OAT3 promoter region may affect the widespread chromatin configuration including the OAT1 gene, enabling DNA methylation-dependent gene silencing of OAT1 in extrarenal tissues. Future studies are required to show the in vivo relevance of the epigenetic regulation for OAT1 expression.
In conclusion, the present study clearly demonstrates that HNF1
/HNF1β heterodimer plays a key role in the constitutive expression of human and mouse OAT1 genes. The transcriptional activation by HNF1 is a common feature among renal organic anion transporters, further emphasizing the role of this transcription factor in the regulation of endobiotics/xenobiotics transport in the kidney.
| Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: OAT, organic anion transporter; URAT, urate transporter; HNF, hepatocyte nuclear factor; hOAT, human OAT; PCR, polymerase chain reaction; mOat, mouse organic anion transporter; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pair; HEK, human embryonic kidney; wt, wild type; mut, mutated wild-type sequence; EMSA, electrophoretic mobility shift assay.
Address correspondence to: Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp
| References |
|---|
|
|
|---|
Blumenfeld M, Maury M, Chouard T, Yaniv M, and Condamine H (1991) Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development 113: 589-599.[Abstract]
Buist SC and Klaassen CD (2004) Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1–3; Slc22a6–8) mRNA levels. Drug Metab Dispos 32: 620-625.
Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, Bachvarova RF, and Darnell JE Jr (1994) Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev 8: 2466-2477.
Cihlar T, Ho ES, Lin DC, and Mulato AS (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20: 641-648.[CrossRef][Medline]
Drewes T, Senkel S, Holewa B, and Ryffel GU (1996) Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 16: 925-931.[Abstract]
Enomoto A and Endou H (2005) Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9: 195-205.[CrossRef][Medline]
Eraly SA, Hamilton BA, and Nigam SK (2003) Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun 300: 333-342.[CrossRef][Medline]
Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, Monte JC, Rieg T, Truong DM, Long JM, et al. (2006) Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem 281: 5072-5083.
Fraser JD, Martinez V, Straney R, and Briggs MR (1998) DNA binding and transcription activation specificity of hepatocyte nuclear factor 4. Nucleic Acids Res 26: 2702-2707.
Gresh L, Fischer E, Reimann A, Tanguy M, Garbay S, Shao X, Hiesberger T, Fiette L, Igarashi P, Yaniv M, et al. (2004) A transcriptional network in polycystic kidney disease. EMBO J 23: 1657-1668.[CrossRef][Medline]
Ho ES, Lin DC, Mendel DB, and Cihlar T (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 11: 383-393.
Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276: F122-F128.[Medline]
Jiang S, Tanaka T, Iwanari H, Hotta H, Yamashita H, Kumakura J, Watanabe Y, Uchiyama Y, Aburatani H, Hamakubo T, et al. (2003) Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4
(HNF4
) isoforms in human and rats. Nucl Recept 1: 5.[CrossRef][Medline]
Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, and Kullak-Ublick GA (2001) Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1
. J Biol Chem 276: 37206-37214.
Kikuchi R, Kusuhara H, Hattori N, Kim I, Shiota K, Gonzalez FJ, and Sugiyama Y (2007) Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1
β and DNA methylation. Mol Pharmacol 72: 1619-1625.
Kikuchi R, Kusuhara H, Hattori N, Shiota K, Kim I, Gonzalez FJ, and Sugiyama Y (2006) Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1
β and DNA methylation. Mol Pharmacol 70: 887-896.
Lazzaro D, De Simone V, De Magistris L, Lehtonen E, and Cortese R (1992) LFB1 and LFB3 homeoproteins are sequentially expressed during kidney development. Development 114: 469-479.[Abstract]
Lee YH, Sauer B, and Gonzalez FJ (1998) Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1
knockout mouse. Mol Cell Biol 18: 3059-3068.
Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, and Klaassen CD (2006) Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1
. Biochem Pharmacol 72: 512-522.[CrossRef][Medline]
Mendel DB and Crabtree GR (1991) HNF-1, a member of a novel class of dimerizing homeodomain proteins. J Biol Chem 266: 677-680.
Miquerol L, Lopez S, Cartier N, Tulliez M, Raymondjean M, and Kahn A (1994) Expression of the L-type pyruvate kinase gene and the hepatocyte nuclear factor 4 transcription factor in exocrine and endocrine pancreas. J Biol Chem 269: 8944-8951.
Ogasawara K, Terada T, Asaka J, Katsura T, and Inui K (2007) Hepatocyte nuclear factor-4
regulates the human organic anion transporter 1 gene in the kidney. Am J Physiol Renal Physiol 292: F1819-F1826.
Podvinec M, Kaufmann MR, Handschin C, and Meyer UA (2002) NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol 16: 1269-1279.
Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, and Yaniv M (1996) Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575-585.[CrossRef][Medline]
Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, and Kullak-Ublick GA (2005) The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4
and suppressed by bile acids. Mol Pharmacol 67: 1629-1638.
Prieur X, Schaap FG, Coste H, and Rodriguez JC (2005) Hepatocyte nuclear factor-4
regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-
coactivator-1
, AMP-activated protein kinase, and mitogen-activated protein kinase pathway. Mol Endocrinol 19: 3107-3125.
Rey-Campos J, Chouard T, Yaniv M, and Cereghini S (1991) vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. EMBO J 10: 1445-1457.[Medline]
Saborowski M, Kullak-Ublick GA, and Eloranta JJ (2006) The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4
. J Pharmacol Exp Ther 317: 778-785.
Sekine T, Miyazaki H, and Endou H (2006) Molecular physiology of renal organic anion transporters. Am J Physiol Renal Physiol 290: F251-F261.
Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, et al. (2001) Hepatocyte nuclear factor-1
is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 27: 375-382.[CrossRef][Medline]
Sladek FM, Zhong WM, Lai E, and Darnell JE Jr (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4: 2353-2365.
Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, and Nigam SK (2002) Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 277: 26934-26943.
Tronche F and Yaniv M (1992) HNF1, a homeoprotein member of the hepatic transcription regulatory network. Bioessays 14: 579-587.[CrossRef][Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||